Table 2.
Association analysis of genes polymorphisms with the response to antiviral treatment
| Genotype/ Allele | SVR | NR | P value | OR(95%CI) |
|---|---|---|---|---|
| N = 91 | N = 109 | |||
| CYP2R1 rs10741657 [n(%)] | Chi2 = 5.38 p = 0.06 | |||
| A/A | 7(7.7) | 4(3.7) | ||
| A/G | 44(48.4) | 40(36.7) | ||
| G/G | 40(44) | 59.6))65 | 0.028 | 0.531(0.302-0.933) |
| A allele carriers/A allele non carriers | 51/40 | 44/65 | 0.027 | 1.884(1.072-3.310) |
| VDR rs2228570 [n(%)] | Chi2 = 8.66 p = 0.013 | |||
| A/A | 13(14.3) | 4(3.7) | 0.013 | 4.375(1.374-13.932) |
| A/G | 36(39.6) | 39(35.8) | ||
| G/G | 42(46.2) | 66(60.6) | ||
| A allele carriers/A allele non carriers | 49/42 | 43/66 | 0.042 | 1.791(1.019-3.146) |
| VDR rs1544410 [n(%)] | n.s. | |||
| C/C | 30(33) | 38(34.9) | ||
| C/T | 39(42.9) | 47(43.1) | ||
| T/T | 22(24.9) | 24(22) | ||
| T allele carriers/ T allele non carriers | 61/30 | 71/38 | ||
| OASL rs1169279 [n(%)] | Chi2 = 5.4 p = 0.06 | |||
| C/C | 19(20.9) | 39(55.8) | 0.022 | 0.474(0.250-0.898) |
| C/T | 52(57.1) | 49(45) | ||
| T/T | 20(22) | 21(19.3) | ||
| T allele carriers/ T allele non carriers | 72/19 | 70/39 | 0.013 | 2.26(1.182-4.318) |
| ADAR rs1127309 [n(%)] | n.s. | |||
| C/C | 30(33) | 38(34.9) | ||
| C/T | 39(42.9) | 47(43.1) | ||
| T/T | 22(24.2) | 24(22) | ||
| T allele carriers/ T allele non carriers | 61/30 | 71/109 | ||
OR, odds ratio; 95%CI Confidence Interval; n.s., non-significant; SVR: sustained viral response; NR: non response; CYP2R1: cytochrome P-450 family 2, subfamily R; VDR: vitamin D receptor; OASL: oligoadenylate synthetases-like; ADAR: adenosine deaminases acting on RNA
Chi-square test for genotype distribution